Phaseline

Companies › Acrivon Therapeutics

Acrivon Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Prexasertib (ACR-368)
Serine/threonine-protein kinase Chk1 inhibitor; Serine/threonine-protein kinase Chk2 inhibitor
CHEK1, CHEK2Phase 2Endometrial Adenocarcinoma; Head and Neck Squamous Cell CarcinomaMay 2027
ACR-2316–Phase 1Specific Advanced Solid TumorsAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05548296Prexasertib (ACR-368)Phase 2Endometrial AdenocarcinomaOncologyMay 2027
NCT06667141ACR-2316Phase 1Specific Advanced Solid TumorsOncologyAug 2027
NCT06597565Prexasertib (ACR-368)Phase 2Head and Neck Squamous Cell CarcinomaOncologyAug 2028

From the company's SEC filings

Cash and short-term investments of $90m on 2026-06-30; operating cash outflow about $72m a year; runway about 15 months at that burn, to Sep 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CHEK1 (1) CHEK2 (1)

Companies with the same targets

PharmaEngine

Companies built like this

Cellectar Biosciences Allarity Therapeutics ALX Oncology CNS Pharmaceuticals Eikon Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.